Please login to the form below
tenofovir disoproxil
This page shows the latest tenofovir disoproxil news and features for those working in and with pharma, biotech and healthcare.
GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention
The studies demonstrated that cabotegravir long-acting for PrEP was superior to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), with clinical trial participants experiencing a 69% lower rate of HIV
Latest news
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
disoproxil) and Atripla (efavirenz/emtricitabine/tenofovir) in the United States. ... The drop was also partially offset by a 20% increase to $2.3bn from Biktarvy (bictegravir/emtricitabine/tenofovir) and Trodelvy (sacituzumab govitecan-hziy), said Gilead
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
However, total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020, due to the loss of exclusivity of its HIV drugs Truvada, tenofovir disoproxil fumarate and
-
Gilead set to acquire hepatitis specialist MYR for €1.15bn
In the phase 2 MYR202 study, 54 of 90 patients treated with Hepcludex and tenofovir disoproxil fumarate (TDF) had at least a 2 log10 HDV RNA decline or undetectable HDV RNA
-
NHS England will make PrEP for HIV available in April
The PrEP Impact Trial is using Mylan's generic version of Gilead Sciences’ antiretroviral therapy Truvada (emtricitabine/tenofovir disoproxil) but is due to come to an end in October.
-
Gilead builds case for Descovy PrEP after FDA approval
Descovy (emtricitabine/tenofovir alafenamide) claimed its FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green
More from news
Approximately 5 fully matching, plus 42 partially matching documents found.
Latest Intelligence
-
Choices, choices: the rapidly evolving HIV treatment landscape
With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Collected Group
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
